Free Trial

Prothena (PRTA) News Today

Prothena logo
$4.59 -0.11 (-2.34%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$4.66 +0.07 (+1.42%)
As of 05/30/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Why is Prothena Down Today?

Prothena Co. plc (NASDAQ:PRTA) shares are trading lower after analysts cut earnings estimates and ratings amid clinical trial setbacks.

The moves follow the May 23 announcement that the Phase 3 AFFIRM-AL trial for Birtamimab in AL Amyloidosis patients failed to meet its primary endpoint, prompting multiple price target reductions.

  • H.C. Wainwright maintains a Buy rating on PRTA.
  • Chardan Capital retains its Buy rating with an $18 price objective.
  • Piper Sandler cuts its price target to $81.
  • Oppenheimer downgrades the stock to Perform from Outperform.
  • Bank of America lowers its rating to Underperform and sets a $4 target.
  • Chardan Capital cuts FY2025 EPS estimate to ($3.80); HC Wainwright cuts FY2027 EPS to ($5.44).
  • Multiple analysts (BofA Securities, Piper Sandler, Oppenheimer) issue pessimistic forecasts following the trial failure.
Posted 1+ days agoAI Generated. May Contain Errors.

PRTA Latest News

Prothena Co. plc stock logo
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of "Hold" by Brokerages
Prothena Co. plc (NASDAQ:PRTA - Get Free Report) has been assigned a consensus rating of "Hold" from the nine brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a
Prothena Co. plc stock logo
FY2025 EPS Estimates for Prothena Cut by Chardan Capital
Prothena Co. plc (NASDAQ:PRTA - Free Report) - Equities researchers at Chardan Capital reduced their FY2025 earnings per share (EPS) estimates for Prothena in a research note issued on Tuesday, May 27th. Chardan Capital analyst R. Li now anticipates that the biotechnology company will post earnin
HC Wainwright Has Weak Outlook for Prothena FY2027 Earnings
Prothena Co. plc stock logo
FY2027 EPS Estimates for Prothena Decreased by HC Wainwright
Prothena Co. plc (NASDAQ:PRTA - Free Report) - HC Wainwright dropped their FY2027 earnings per share estimates for shares of Prothena in a note issued to investors on Tuesday, May 27th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn ($5.44) per share for the
Prothena Co. plc stock logo
Wellington Management Group LLP Increases Position in Prothena Co. plc (NASDAQ:PRTA)
Wellington Management Group LLP increased its stake in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 22.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,130,876 shares of the biotechnology company'
Prothena (NASDAQ:PRTA) Given Underperform Rating at Bank of America
Prothena Co. plc stock logo
Prothena (NASDAQ:PRTA) Lowered to Underperform Rating by Bank of America
Bank of America lowered shares of Prothena from a "neutral" rating to an "underperform" rating and set a $4.00 price target on the stock. in a research report on Wednesday.
Prothena (NASDAQ:PRTA) Stock Rating Lowered by Oppenheimer
Prothena Co. plc stock logo
Piper Sandler Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock Price
Piper Sandler cut their price objective on Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research report on Tuesday.
Prothena Co. plc stock logo
Prothena Target of Unusually High Options Trading (NASDAQ:PRTA)
Prothena Co. plc (NASDAQ:PRTA - Get Free Report) saw unusually large options trading activity on Tuesday. Traders purchased 8,185 put options on the stock. This represents an increase of approximately 1,210% compared to the average volume of 625 put options.
Prothena Co. plc stock logo
JMP Securities Cuts Prothena (NASDAQ:PRTA) Price Target to $29.00
JMP Securities decreased their price objective on shares of Prothena from $78.00 to $29.00 and set a "market outperform" rating on the stock in a research report on Tuesday.
Prothena Co. plc stock logo
Prothena (NASDAQ:PRTA) Downgraded by Cantor Fitzgerald to Neutral
Cantor Fitzgerald downgraded Prothena from an "overweight" rating to a "neutral" rating in a research note on Tuesday.
Prothena Co. plc stock logo
Prothena (NASDAQ:PRTA) Downgraded by Jefferies Financial Group to Hold
Jefferies Financial Group lowered Prothena from a "buy" rating to a "hold" rating and set a $6.00 target price on the stock. in a research report on Tuesday.
Prothena Co. plc stock logo
Prothena (NASDAQ:PRTA) Cut to Market Perform at Oppenheimer
Oppenheimer downgraded shares of Prothena from an "outperform" rating to a "market perform" rating in a research report on Tuesday.
Prothena Co. plc stock logo
Chardan Capital Lowers Prothena (NASDAQ:PRTA) Price Target to $18.00
Chardan Capital decreased their target price on Prothena from $40.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday.
Prothena Co. plc stock logo
HC Wainwright Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock Price
HC Wainwright lowered their target price on shares of Prothena from $30.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday.
Prothena Co. plc stock logo
Deutsche Bank AG Purchases 63,512 Shares of Prothena Co. plc (NASDAQ:PRTA)
Deutsche Bank AG raised its position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 195.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,970 shares of the biotechnology company's stock after acq
Prothena Co. plc stock logo
BNP Paribas Financial Markets Purchases 41,541 Shares of Prothena Co. plc (NASDAQ:PRTA)
BNP Paribas Financial Markets lifted its holdings in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 74.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 97,383 shares of the biotechnology company's stock after purchasing an
Prothena Co. plc stock logo
Balyasny Asset Management L.P. Makes New $527,000 Investment in Prothena Co. plc (NASDAQ:PRTA)
Balyasny Asset Management L.P. acquired a new position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 38,021 shares of the biotechnology company
Prothena Co. plc stock logo
Cantor Fitzgerald Upgrades Prothena (NASDAQ:PRTA) to "Strong-Buy"
Cantor Fitzgerald upgraded Prothena to a "strong-buy" rating in a research report on Tuesday.
Prothena Co. plc stock logo
Prosight Management LP Sells 65,345 Shares of Prothena Co. plc (NASDAQ:PRTA)
Prosight Management LP lessened its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 13.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 418,122 shares of the biotechnology company's stock after sell
Prothena Co. plc stock logo
Cantor Fitzgerald Expects Increased Earnings for Prothena
Prothena Co. plc (NASDAQ:PRTA - Free Report) - Equities researchers at Cantor Fitzgerald upped their FY2025 EPS estimates for shares of Prothena in a research note issued on Monday, May 12th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biotechnology company will post earnings of ($
Prothena Co. plc stock logo
Prothena (NASDAQ:PRTA) Issues Quarterly Earnings Results
Prothena (NASDAQ:PRTA - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The business had revenue of $2.83 million during the quarter, compared to analysts' expectations of $8.18 million. During the same period in the prior year, the firm posted ($1.34) EPS. Prothena's revenue for the quarter was up 5500.0% compared to the same quarter last year.
Prothena Co. plc stock logo
Prothena (NASDAQ:PRTA) Receives "Buy" Rating from Chardan Capital
Chardan Capital restated a "buy" rating and set a $40.00 target price on shares of Prothena in a report on Friday.
Get Prothena News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

PRTA Media Mentions By Week

PRTA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PRTA
News Sentiment

-0.33

0.88

Average
Medical
News Sentiment

PRTA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PRTA Articles
This Week

53

5

PRTA Articles
Average Week

Get Prothena News Delivered to You Automatically

Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:PRTA) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners